Nektar Therapeutics Operating Lease, Liability, Noncurrent
Nektar Therapeutics (NKTR) had Operating Lease, Liability, Noncurrent of $55.85 million as of 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2026-08-14
- 2026-06-30: Operating Lease, Liability, Noncurrent $55.85M.
- 2026-03-31: Operating Lease, Liability, Noncurrent $60.63M.
- 2025-12-31: Operating Lease, Liability, Noncurrent $65.26M.
- 2025-09-30: Operating Lease, Liability, Noncurrent $69.73M.
| Period end | Operating Lease, Liability, Noncurrent |
|---|---|
| 2026-06-30 | $55.85M 10-Q · filed 2026-08-14 |
| 2026-03-31 | $60.63M 10-Q · filed 2026-05-08 |
| 2025-12-31 | $65.26M 10-Q · filed 2026-08-14 |
| 2025-09-30 | $69.73M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $74.14M 10-Q · filed 2025-08-08 |
| 2025-03-31 | $78.50M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $82.70M 10-K · filed 2026-03-13 |
| 2024-09-30 | $86.76M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $90.76M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $94.71M 10-Q · filed 2024-05-10 |
| 2023-12-31 | $98.52M 10-K · filed 2025-03-14 |
| 2023-09-30 | $102.19M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $105.82M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $109.39M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $112.83M 10-K · filed 2024-03-05 |
| 2022-09-30 | $116.14M 10-Q · filed 2022-11-04 |
| 2022-06-30 | $119.42M 10-Q · filed 2022-08-05 |
| 2022-03-31 | $122.64M 10-Q · filed 2022-05-06 |
| 2021-12-31 | $125.74M 10-K · filed 2023-02-28 |
| 2021-09-30 | $128.72M 10-Q · filed 2021-11-05 |
| 2021-06-30 | $131.66M 10-Q · filed 2021-08-06 |
| 2021-03-31 | $134.56M 10-Q · filed 2021-05-07 |
| 2020-12-31 | $136.37M 10-K · filed 2022-03-01 |
| 2020-09-30 | $139.02M 10-Q · filed 2020-11-06 |
| 2020-06-30 | $141.63M 10-Q · filed 2020-08-07 |
| 2020-03-31 | $142.30M 10-Q · filed 2020-05-08 |
| 2019-12-31 | $142.73M 10-K · filed 2021-02-26 |
| 2019-09-30 | $145.10M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $94.82M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $95.02M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |